Panacea Life Sciences Holdings, Inc. (PLSH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Panacea Life Sciences Holdings, Inc. (PLSH) trades at $0.08248. Panacea Life Sciences Holdings, Inc. is a seed-to-sale cannabinoid and nutraceutical manufacturer focused on developing natural alternatives for consumers and pets. Market cap: $1.75M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for PLSH: PLSH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PLSH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on PLSH.
How is this calculated? →Panacea Life Sciences Holdings, Inc. (PLSH) Healthcare & Pipeline Overview
Panacea Life Sciences Holdings, Inc. develops and manufactures cannabinoid and nutraceutical products, including softgels, gummies, and topicals, targeting both consumer and pet markets. The company operates in the specialty drug manufacturing sector, leveraging a seed-to-sale model and offering white-label and contract manufacturing services.
What Is the Investment Thesis for PLSH?
Panacea Life Sciences Holdings, Inc. presents a unique investment proposition within the cannabinoid and nutraceutical sector. With a market capitalization of $1.75M and a P/E ratio of 0.48, the company demonstrates potential value. A gross margin of 69.4% and a profit margin of 237.0% indicate strong operational efficiency. Key growth catalysts include expansion of its white-label manufacturing services and increased penetration into the consumer and pet markets. However, the company's high beta of 3.31 suggests significant volatility. The investment thesis hinges on Panacea Life Sciences' ability to scale its production, navigate regulatory landscapes, and capitalize on the increasing acceptance of cannabinoid products. Success in these areas could drive revenue growth and enhance shareholder value.
Based on FMP financials and quantitative analysis
PLSH Key Highlights
Profit Margin of 237.0% indicates strong profitability in its operations.
- Gross Margin of 69.4% reflects efficient cost management in production.
- Involvement in white label and contract manufacturing provides diversified revenue streams.
- Seed-to-sale model ensures control over product quality and supply chain.
- Beta of 3.31 suggests high volatility compared to the market.
Who Are PLSH's Competitors?
PLSH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PLSH's Key Strengths?
Seed-to-sale model ensures quality control.
- Diverse product portfolio caters to multiple markets.
- White-label and contract manufacturing services provide revenue diversification.
- Established manufacturing capabilities.
What Are PLSH's Weaknesses?
Small market capitalization limits access to capital.
- High beta indicates significant volatility.
- Dependence on regulatory environment for cannabinoid products.
- Limited brand recognition compared to larger competitors.
What Could Drive PLSH Stock Higher?
Expansion of white-label and contract manufacturing services to increase revenue streams.
- Increased penetration into the pet market with targeted cannabinoid products.
- Potential regulatory changes in key markets that could expand market access.
- Launch of new innovative cannabinoid formulations to enhance market share.
- Strategic partnerships with retailers and distributors to expand market reach.
What Are the Key Risks for PLSH?
Financial-distress signal — its Altman Z-Score of -45.88 sits in the distress zone (elevated bankruptcy risk).
- Changing regulatory landscape for cannabinoid products could impact market access.
- Competition from larger, more established companies with greater resources.
- Fluctuations in raw material prices could affect profit margins.
- Product recalls or safety concerns could damage brand reputation.
- Limited access to capital due to small market capitalization.
What Are the Growth Opportunities for PLSH?
- Expansion of White-Label and Contract Manufacturing Services: Panacea Life Sciences can leverage its manufacturing capabilities to offer white-label and contract manufacturing services to other cannabinoid companies. The market for outsourced manufacturing in the cannabinoid sector is growing, driven by companies seeking to reduce capital expenditures and focus on branding and marketing. This represents a significant revenue opportunity, potentially contributing to a 20% increase in revenue within the next two years.
- Increased Penetration into the Pet Market: The market for cannabinoid-based products for pets is expanding rapidly as pet owners seek natural solutions for their animals' health and well-being. Panacea Life Sciences can capitalize on this trend by developing and marketing targeted products for pets, such as softgels and tinctures. This market segment could contribute to a 15% increase in revenue within the next three years.
- Development of Innovative Cannabinoid Formulations: Investing in research and development to create innovative cannabinoid formulations can provide a competitive edge. This includes developing new delivery methods, such as sublingual tablets and topical applications, that enhance bioavailability and consumer convenience. Successful innovation could lead to a 10% increase in market share within the next five years.
- Strategic Partnerships with Retailers and Distributors: Forming strategic partnerships with retailers and distributors can expand Panacea Life Sciences' market reach and increase product availability. This includes partnering with both online and brick-and-mortar retailers to reach a wider customer base. Such partnerships could result in a 25% increase in sales volume within the next two years.
- Expansion into International Markets: Exploring opportunities to expand into international markets, particularly in regions with favorable regulatory environments for cannabinoid products, can drive significant growth. This requires careful market analysis and regulatory compliance, but the potential rewards are substantial. International expansion could contribute to a 30% increase in revenue within the next five years.
What Are PLSH's Competitive Advantages?
- Seed-to-sale model ensures quality control and supply chain management.
- Diverse product portfolio caters to both consumer and pet markets.
- White-label and contract manufacturing services provide diversified revenue streams.
- Established manufacturing capabilities and expertise in cannabinoid extraction and formulation.
What Does PLSH Do?
Panacea Life Sciences Holdings, Inc., established in 2008 and headquartered in Greenwood Village, Colorado, operates as a seed-to-sale cannabinoid and nutraceutical manufacturer. The company focuses on developing and producing natural pharmaceutical alternatives for both consumers and pets. Its product portfolio includes a diverse range of cannabinoid-based products such as softgels, gummies, tinctures, sublingual tablets, cosmetics, and topical applications. In addition to its core product lines, Panacea Life Sciences is involved in white label and contract manufacturing sales to other cannabinoid companies, raw material sales, and tolling arrangements. The company also participates in the personal protection equipment (PPE) market, importing and selling PPE, including hand sanitizers and masks. This diversification reflects an adaptive strategy to leverage market opportunities and expand its revenue streams. Panacea Life Sciences aims to provide comprehensive cannabinoid solutions, from cultivation to finished products, catering to the growing demand for natural health alternatives.
What Products and Services Does PLSH Offer?
- Develops and manufactures cannabinoid-based products.
- Produces nutraceutical products for consumers and pets.
- Offers softgels, gummies, tinctures, and topical applications.
- Provides white label and contract manufacturing services.
- Sells raw materials to other cannabinoid companies.
- Engages in tolling arrangements for cannabinoid processing.
- Imports and sells personal protection equipment (PPE).
How Does PLSH Make Money?
- Seed-to-sale production of cannabinoid and nutraceutical products.
- Revenue generation through direct sales to consumers and retailers.
- White-label and contract manufacturing services for other companies.
- Sales of raw materials and tolling services.
What Industry Does PLSH Operate In?
Panacea Life Sciences Holdings, Inc. operates within the rapidly evolving cannabinoid and nutraceuticals market. This sector is characterized by increasing consumer demand for natural health alternatives and expanding regulatory acceptance of cannabinoid products. The competitive landscape includes companies like ALID, ANTCF, BHNGF, CBDY, and CNNA, all vying for market share. Panacea Life Sciences differentiates itself through its seed-to-sale model, ensuring quality control and supply chain management. The market is subject to regulatory changes and evolving consumer preferences, requiring companies to adapt quickly to maintain competitiveness.
Who Are PLSH's Key Customers?
- Consumers seeking natural health alternatives.
- Pet owners looking for cannabinoid-based products for their pets.
- Other cannabinoid companies requiring manufacturing services.
- Retailers and distributors of health and wellness products.
Insider Activity
The most recent 12 insider filings for Panacea Life Sciences Holdings, Inc. break down as 0 sales and 12 purchases. On net that is roughly 815K shares acquired (about $400K) — insiders putting money in tends to read as conviction.
PLSH Valuation & Market Position
With a $1.75M market cap, Panacea Life Sciences Holdings, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Its free cash flow yield is -1.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -153.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Panacea Life Sciences Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -45.88 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Panacea Life Sciences Holdings, Inc. revenue of about $956K for fiscal 2026, with EPS near $-22.40.
Company Profile
Panacea Life Sciences Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Greenwood Village, US. The company is led by CEO Leslie A. Buttorff. PLSH has traded publicly since 2022.
PLSH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Seed-to-sale model ensures quality control.
- Diverse product portfolio caters to multiple markets.
- White-label and contract manufacturing services provide revenue diversification.
- Established manufacturing capabilities.
Bear Case
- Small market capitalization limits access to capital.
- High beta indicates significant volatility.
- Dependence on regulatory environment for cannabinoid products.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PLSH Latest News
No recent news available for PLSH.
PLSH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PLSH.
Price Targets
Wall Street price target analysis for PLSH.
PLSH MoonshotScore
What does this score mean?
The MoonshotScore rates PLSH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Leslie A. Buttorff
CEO
Leslie A. Buttorff serves as the CEO of Panacea Life Sciences Holdings, Inc. Her background includes extensive experience in managing and scaling businesses, with a focus on the healthcare and life sciences sectors. She has a proven track record of driving revenue growth, implementing operational efficiencies, and developing strategic partnerships. Her leadership is instrumental in guiding Panacea Life Sciences through the evolving cannabinoid and nutraceutical market.
Track Record: Under Leslie A. Buttorff's leadership, Panacea Life Sciences has expanded its product portfolio, increased its manufacturing capabilities, and diversified its revenue streams. She has overseen the company's entry into the white-label and contract manufacturing market, as well as its expansion into the pet market. Her strategic decisions have positioned Panacea Life Sciences for continued growth and success.
PLSH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Panacea Life Sciences Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier are often speculative and carry higher risks due to limited information and regulatory oversight. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies have less stringent listing requirements, resulting in increased potential for volatility and information asymmetry.
- OTC Tier: OTC Other
- Limited Financial Disclosure: Lack of comprehensive and timely financial reporting increases investment risk.
- Low Liquidity: Difficulty in buying or selling shares can lead to significant price volatility.
- Regulatory Uncertainty: OTC Other companies are subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- Speculative Nature: Many OTC Other stocks are highly speculative and may not have viable business models.
- Potential for Price Manipulation: Low trading volume makes these stocks susceptible to price manipulation.
- Verify the company's financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Review the company's regulatory filings and compliance history.
- Analyze the company's capital structure and debt levels.
- Check for any legal or regulatory issues.
- Understand the risks associated with investing in OTC Other stocks.
- Established Manufacturing Facilities: The company has operational manufacturing facilities.
- Seed-to-Sale Model: The company controls its supply chain from cultivation to finished products.
- Diverse Product Portfolio: The company offers a range of cannabinoid and nutraceutical products.
- White-Label Services: The company provides manufacturing services to other companies, indicating industry recognition.
- CEO Leadership: Experienced CEO leading the company.
What Investors Ask About Panacea Life Sciences Holdings, Inc. (PLSH) — Healthcare
What does Panacea Life Sciences Holdings, Inc. do?
Panacea Life Sciences Holdings, Inc. operates as a seed-to-sale cannabinoid and nutraceutical manufacturer, focusing on developing and producing natural pharmaceutical alternatives for consumers and pets. The company manufactures and sells a variety of cannabinoid-based products, including softgels, gummies, tinctures, and topical applications.
What do analysts say about PLSH stock?
As of 2026-03-15, formal analyst coverage of Panacea Life Sciences Holdings, Inc. (PLSH) appears limited, likely due to its OTC listing and small market capitalization. Key valuation metrics include a P/E ratio of 0.48, a gross margin of 69.4%, and a profit margin of 237.0%.
What are the main risks for PLSH?
The main risks for Panacea Life Sciences Holdings, Inc. include the evolving regulatory landscape for cannabinoid products, which could impact market access and compliance costs. Competition from larger, more established companies with greater resources poses a significant threat. Fluctuations in raw material prices could affect profit margins, and potential product recalls or safety concerns could damage brand reputation.
How does Panacea Life Sciences Holdings, Inc. navigate regulatory approval processes?
Panacea Life Sciences Holdings, Inc. operates in a complex regulatory environment, given the evolving legal status of cannabinoid products. The company must comply with federal, state, and local regulations regarding the cultivation, manufacturing, and sale of its products.
How does Panacea Life Sciences Holdings, Inc. manage patent expiration risks?
As a manufacturer of cannabinoid and nutraceutical products, Panacea Life Sciences Holdings, Inc. may face patent-related risks, particularly concerning novel formulations or delivery methods. While the company's core products may not be heavily reliant on patented technologies, it must be aware of potential intellectual property infringement issues.
What are the key factors to evaluate for PLSH?
Evaluate PLSH on fundamentals, analyst consensus, and risk factors. Panacea Life Sciences Holdings, Inc. presents a unique investment proposition within the cannabinoid and nutraceutical sector. Not financial advice.
How frequently does PLSH data refresh on this page?
PLSH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PLSH's recent stock price performance?
Panacea Life Sciences Holdings, Inc. (PLSH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Seed-to-sale model ensures quality control. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- Financial data is based on available information and may be limited.